RJA
ELGX

Raymond James & Associates’s Endologix Inc ELGX Stock Holding History

Raymond James & Associates’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,101
Closed -$141K – 3415
2016
Q3 		$141K Sell
1,101
-500
-31% -$64K ﹤0.01% 2945
2016
Q2 		$200K Buy
+1,601
New +$184K ﹤0.01% 2661

Other funds holding ELGX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Raymond James & Associates's ELGX Position: Q4 2016 in Review

Raymond James & Associates sold out of Endologix Inc (ELGX) in Q4 2016, closing a stake of 1,101 shares — an estimated $141K sold.

Raymond James & Associates first reported a position in ELGX in Q2 2016 and held it in 2 quarters. The position peaked at $200K in Q2 2016. 140 funds tracked by Wall St. Rank hold ELGX as of Q4 2016.

  • Raymond James & Associates reported no remaining Endologix Inc position as of Q4 2016 after selling out during the quarter.
  • Raymond James & Associates sold 1,101 Endologix Inc shares in Q4 2016, an estimated $141K.
  • Raymond James & Associates first reported a position in Endologix Inc in Q2 2016 and held it in 2 quarters.
  • Raymond James & Associates's Endologix Inc position peaked at $200K in Q2 2016.
  • 140 funds tracked by Wall St. Rank held Endologix Inc as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.